Publications

Harris AE, Lothion-Roy J, Thompson RL, Haque M, Woodcock CL, Alsaleem MA, Dean A, Kariri Y, Toss MS, Gudas LJ et al..  2025.  Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer.. NPJ Breast Cancer. 11(1):147.

Harris AE, Lothion-Roy J, Thompson RL, Haque M, Woodcock CL, Alsaleem MA, Dean A, Kariri Y, Toss MS, Gudas LJ et al..  2025.  Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer.. NPJ Breast Cancer. 11(1):147.

Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.

Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.

Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, Kariri Y, Ntekim A, Robinson BD, Khani F et al..  2022.  Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.. Front Genet. 13:1096071.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, Kariri Y, Ntekim A, Robinson BD, Khani F et al..  2022.  Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.. Front Genet. 13:1096071.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, Kariri Y, Ntekim A, Robinson BD, Khani F et al..  2022.  Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.. Front Genet. 13:1096071.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)

Laursen KB, Chen Q, Khani F, Attarwala N, Gross SS, Dow L, Nanus DM, Gudas LJ.  2021.  Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.. Front Oncol. 11:783856.

Melis M, Tang X-H, Attarwala N, Chen Q, Prishker C, Qin L, Gross SS, Gudas LJ, Trasino SE.  2021.  A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes.. Biofactors.

Trasino SE, Tang X-H, Trujillo C, Andres J, Ehrt S, Gudas LJ.  2020.  Mycobacterium tuberculosis infection is exacerbated in mice lacking lecithin:retinol acyltransferase.. Biochim Biophys Acta Mol Basis Dis. 1866(11):165909.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

Sureshbabu A, Patino E, Ma KC, Laursen K, Finkelsztein EJ, Akchurin O, Muthukumar T, Ryter SW, Gudas L, Choi AMK et al..  2018.  RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction.. JCI Insight. 3(11)

Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, Mongan NP, Gudas LJ, Persson JL.  2013.  CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.. Cell Cycle. 12(8):1251-66.

Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JLiao, Gudas LJ, Mongan NP.  2013.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.. Mol Oncol. 7(3):555-66.

Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.  2012.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).. Int J Oncol. 40(1):5-12.

Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.  2012.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).. Int J Oncol. 40(1):5-12.

Amat R, Gudas LJ.  2011.  RARγ is required for correct deposition and removal of Suz12 and H2A.Z in embryonic stem cells.. J Cell Physiol. 226(2):293-8.

Agrawal V, Johnson SA, Reing J, Zhang L, Tottey S, Wang G, Hirschi KK, Braunhut S, Gudas LJ, Badylak SF.  2010.  Epimorphic regeneration approach to tissue replacement in adult mammals.. Proc Natl Acad Sci U S A. 107(8):3351-5.

Tang X-H, Albert M, Scognamiglio T, Gudas LJ.  2009.  A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.. Cancer Prev Res (Phila). 2(12):1100-10.